This compilation of papers is probably not as useful as other better resources which compile this information, such as Critical Care Reviews and The Bottom Line. However, it is probably at least harmless. Wherever possible, the original paper is linked from the name of the study, and the Bottom Line review is linked from the year of publication.
ALVEOLI - 2004 - what if moar PEEP (8 vs 13)? n=549 in the US. No difference in mortality (24.9% vs 27.5%).
ARDNET Fluids - 2006 - what if less fluids? n=1000 in the US. No difference in mortality (25.5% vs 28.4%) but more ventilator-free days (14.6 vs. 12.1).
LOVS - 2008 - again, what if moar PEEP (9.8 vs 14.6)? n= 983 in Canada, Australia, and Saudi Arabia. No difference in mortality (36.4% vs 40.4%) but reduced use of rescue therapies (5.1% vs 9.3%) and no extra risk of barotrauma.
EXPRESS - 2008 - seriously, open lung again. PEEP of 5-9 vs. PEEP titrated to achieve a Pplat of 28-30. n=767 in France. No difference in mortality (39.0% vs 35.4%) but more ventilator-free days (7 vs 3) and reduced use of rescue therapies (18.7% vs 34.6%).
Kacmarec et al - 2016 - open lung ventilation with recruitment manoeuvre up to PEEP 30; n=200, mostly in Spain. No mortality difference (29% vs 33%) but various ventilator parameters and oxygenation did improve.
PROSEVA - 2013 - prone vs standard ventilation in severe ARDS (n=466 in France). Lower mortality with prone (16.0% vs 32.8%), 16 hours seemed to be the "dose".
PreVENT - 2018 - what if lung-protective volumes, but not in ARDS? 6 vs 10ml/kg. n=961 (Netherlands). No difference in any of the outcomes, because minimal volume separation between groups from Day 1 onwards (7.4 vs 9.1 ml/kg from Day 2).
PHARLAP - 2019 - open-lung with recruitment maneuvers in severe ARDS, n=115 all around the world. No difference in ventilator-free days (16 vs 14.5); but stopped early when the ART trial caused a loss of equipoise.
RECOVERY-RS - 2021 - CPAP vs HFNP vs normal O2 in COVID. n=1277, in the UK. Combined death/intubation endpoint significantly reduced in CPAP (36.3%) vs normal O2 (44.4%) but not in HFNP (44.4%); mainly because of reduced need for intubation.
CLOSE - 2016 - sats 88-92 versus >96%; n=103 in Australia. Feasibility only, demonstrating that it is safe to achieve this sort of separation for 7 days.
LOCO2 - 2020 - PaO2 55-70 vs 70-105 in ARDS. n=201, in France. No significant difference at 28 days, but enough of a difference (34.3% conservative vs. 26.5% liberal) to stop the trial early. Increased signal for risk of mesenteric ischaemia.
PILOT - 2022 - sats 88-92 vs 92-96 vs 96-100. n=2541 in Nashville. No difference in mortality (34.8% vs 34% vs 33.2%) or ventilator-free days (20, 21 and 21).
BREATHE - 2018 - after a failed SBT, do you extubate on to NIV, or wait on PSV? n=364 in the UK. Median time to being off all ventilation was no different (4.3 vs 4.5 days) but the NIV group mostly stayed extubated, so that's a win.
Thile et al - 2022 - T-piece vs PSV (PEEP 0, PS 8), n=969 in France (only patients at high risk of extubation failure). No difference in ventilator free days (27 vs 27)
Blum et al - 2015 - 50mg prednisone for 7 days in non-ICU-level community-acquired pneumonia; n=785 in Switzerland. Median time to clinical stability was shorter in the prednisone grou (3.0 vs 4.4 days)
Torres et al - 2015 - steroids (0.5mg/kg methylpred for 5 days) in severe community-acquired pneumonia with CRP > 150; n=120, in Spain. Less late treatment failure with steroids (composite of death, shock, hypoxia, intubation, and worsening CXR changes)
DEXA-ARDS - 2020 - dexamethasone 20mg for 5 days, then 10mg for another 5 days, in early non-COVID ARDS. n=277 in Spain. Markedly improved ventilator-free days (12.3 vs 7.5) and mortality (21% vs 36%)
Jerjes-Sanchez et al - 1995 - thrombolysis for haemodynamically unstable PE, n=8. All those randomised to receive thrombolysis survived; all of the others died.
Intermediate risk PE ("submassive")
PEITHO - 2014 - what if full dose thrombolysis, but moar data? n=1005 all over the world. Composite outcome of death of haemdiynamic decompensation mich better in the thrombolysis group (2.6% vs 5.6%)
Endovascular clot retrieval for PE
EXPRESS - 2019 - catheter-directed thrombolysis for submassive PE; n= 339 in the US. Improved mortality (3% vs 10%).
COPD and asthma
Oxygen therapy and HFNP